Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared a post on LinkedIn about a recent article by Rupak Desaia et al, published in Current Medical Research and Opinion, adding:
“NSTEMI management is no longer ‘troponin positive chest pain.’
It is a risk stratified emergency pathway.
Recent PubMed indexed guidelines converge on a practical message: high sensitivity cardiac troponin is the biomarker of choice, but NSTEMI diagnosis still requires clinical context, ECG, serial change, and exclusion of alternative causes of myocardial injury. (Byrne et al., 2023; Rao et al., 2025)
Troponin T and troponin I are both valid for diagnosis, but they are not interchangeable.
Each assay has its own thresholds, kinetics, analytical behavior, and confounders.
Troponin T may be more frequently elevated in chronic kidney disease, skeletal muscle disease, and advanced age, while troponin I is often considered more cardiac specific at the molecular level. (Byrne et al., 2023; Desai et al., 2024)
CK, CK MB, LDH, and myoglobin should not drive modern NSTEMI diagnosis when high sensitivity troponin is available.
Their incremental diagnostic value is limited, although CK MB may still have niche roles where troponin is unavailable or in selected reinfarction scenarios. (Byrne et al., 2023)
TTE is not optional in unstable ACS.
It helps identify regional wall motion abnormalities, LV and RV dysfunction, acute mitral regurgitation, ventricular septal rupture, tamponade, pulmonary embolism mimics, aortic pathology, and shock phenotype.
However, echocardiography must never delay catheterization when acute coronary occlusion is suspected. (Byrne et al., 2023)
When is PCI mandatory?
In NSTEMI with shock, refractory ischemia, malignant arrhythmias, acute heart failure, mechanical complications, or hemodynamic instability, the question is not ‘observe or cath.’
It is emergency angiography with PCI if feasible.
In cardiogenic shock, immediate coronary angiography and culprit lesion PCI are recommended, while routine multivessel PCI during the index procedure should generally be avoided. (Byrne et al., 2023; Rao et al., 2025)
For stable NSTEMI, PCI timing depends on risk.
High risk patients, including ruled in NSTEMI, dynamic ST or T wave changes, transient ST elevation, or GRACE score above 140, should generally undergo early invasive angiography within 24 hours. (Byrne et al., 2023)
The modern NSTEMI question is not simply:
‘Is troponin positive?’
It is:
‘Is this type 1 MI, how unstable is the patient, what is the myocardium doing, and how fast must we open the artery?’
References
- Byrne, R. A./. European Heart Journal.
- Rao, S. V., Journal of the American College of Cardiology.
- Desai, R.. Current Medical Research and Opinion.”
Title: A systematic review and meta-analysis evaluating the association of high sensitivity troponin levels with outcomes in patients with stable coronary artery disease
Authors: Rupak Desai, Nanush Damarlapally, Srijan Bareja, Vaishnavi Arote, Srivatsa SuryaVasudevan, Kamya Mehta, Mariam Ashfaque, Yadeshini Jayachandran, Shrikanth Sampath, Alaknanda Behera, Archit Srivatsava, Shariq Nawab, Sriharsha Dadana

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026